Results 111 to 120 of about 9,912 (208)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly

Drug Design, Development and Therapy, 2014
Antoni Sicras-Mainar,1 Ruth Navarro-Artieda2 1Dirección de Planificación, Badalona Serveis Assistencials SA, 2Documentación Médica, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain Background: The aim of this study ...
Sicras-Mainar A, Navarro-Artieda R
doaj  

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

Therapeutics and Clinical Risk Management, 2013
CY Pan,1 XL Wang21Chinese PLA General Hospital, Beijing, People's Republic of China; 2Medical Affairs Department, Beijing Novartis Pharma Co, Ltd, Beijing, People's Republic of ChinaAbstract: Vildagliptin is a selective and potent dipeptidyl ...
Pan CY, Wang XL
doaj  

Docosahexaenoic acid is comparable to vildagliptin in improving hyperglycemia and pancreatic insulin signaling of diabetic rats via SIRT1/Akt/PI3K pathway. [PDF]

Sci Rep
Abo-Saif MA, Werida RH, Mohamed SA, Khedr NF.   +3 more
europepmc   +1 more source

Bioequivalence assessment between two formulations of a film-coated fixed-dose combination of metformin and vildagliptin (850/50mg) in healthy Tunisian subjects under fed conditions. [PDF]

Sci Rep
Ferchichi K, Gaies E, Ben Hammamia S, El Jebari H, Daldoul M, Ghorbel S, Srairi S, Guermazi S, Gorgi Y, Boutiba I, Bouzid K, Abbessi A, Daghfous R, Ben Sassi M, Trabelsi S.   +14 more
europepmc   +1 more source

Emerging role of insulin with incretin therapies for management of type 2 diabetes [PDF]

, 2011
Rupa Ahluwalia, Jiten Vora
core   +1 more source

Vildagliptin and Omarigliptin Differentially Bind to DPP-4 Homodimers and Modulate Osteoclast-Mediated Bone Resorption. [PDF]

Compr Physiol
Aeimlapa R, Panmanee J, Teerapornpuntakit J, Wongdee K, Thongbunchoo J, Panupinthu N, Svasti S, Apaijai N, Sa-Nguanmoo P, Chattipakorn S, Chattipakorn N, Charoenphandhu N.   +11 more
europepmc   +1 more source

Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment. [PDF]

CPT Pharmacometrics Syst Pharmacol
Dias BB, Olivo LB, de Araújo BV.
europepmc   +1 more source

ERRATUM: Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction. [PDF]

J Endocrinol
Apaijai N, Inthachai T, Lekawanvijit S, Chattipakorn SC, Chattipakorn N.   +4 more
europepmc   +1 more source

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan. [PDF]

Drugs Real World Outcomes
Takami A, Terashima G, Tajima T, Yamashita K, Igarashi A.   +4 more
europepmc   +1 more source

Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Zhu X, Wang X, Zhang P, Yang Z, Zhao N, Li J, Shi Y, Zhao Y, Ma J.   +8 more
europepmc   +1 more source